Ovarian cancer cells – proliferation

Ovarian cancer cells – proliferation refers to the pathological expansion of malignant cell populations in ovarian tissue, driven by genetic mutations and dysregulated signaling pathways. This term does not represent a single molecular entity but rather a complex biological phenotype that serves as a primary endpoint for evaluating anti-cancer drug efficacy (National Cancer Institute, 2023). Proliferation in these cells is typically fueled by the activation of pathways such as PI3K/AKT/mTOR and MAPK, as well as defects in DNA repair mechanisms like homologous recombination (PubMed, PMID: 31512983). Therapeutic strategies to inhibit this proliferation include the use of platinum-based agents to induce DNA damage, taxanes to disrupt microtubule dynamics, and PARP inhibitors to exploit synthetic lethality in BRCA-mutant cells (StatPearls, 2023). Because this process involves a multitude of redundant pathways and cell types within the tumor microenvironment, it is categorized as a disease state or assay readout rather than a discrete therapeutic target (NIH, 2022). Clinical monitoring of proliferation rates is essential for assessing treatment response, often utilizing the Ki-67 protein as a cellular marker or CA-125 as a systemic surrogate (PubMed, PMID: 28453012).

Other names

Ovarian cancer cell proliferationOvarian tumor growthOvarian cancer cell division

Inhibition of DNA replication, repair, and mitotic spindle assembly to induce cell cycle arrest and apoptosis in malignant ovarian cells.